Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -447.51M | 159.05M | 33.61M | 6.46M | 36.12M |
| Total Depreciation and Amortization | 9.98M | 10.46M | 9.81M | 8.72M | 8.74M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 135.87M | 47.54M | 102.51M | 45.14M | 42.67M |
| Change in Net Operating Assets | -281.78M | -124.99M | -216.62M | -45.38M | -329.61M |
| Cash from Operations | -583.44M | 92.05M | -70.70M | 14.94M | -242.08M |
| Capital Expenditure | -43.65M | -38.08M | -37.26M | -29.17M | -32.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -247.53M | 802.20M | -91.56M | -69.36M | 251.24M |
| Cash from Investing | -291.18M | 764.12M | -128.83M | -98.53M | 218.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.21M | -68.00K | -- | -- | -- |
| Issuance of Common Stock | 15.68M | 3.71M | 13.76M | 39.92M | 22.14M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 45.35M | -- | -- | -- |
| Cash from Financing | 12.47M | 48.99M | 13.76M | 39.92M | 22.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -862.14M | 905.16M | -185.77M | -43.67M | -1.14M |